Copyright
©The Author(s) 2023.
World J Gastrointest Surg. Apr 27, 2023; 15(4): 712-722
Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.712
Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.712
Table 5 The levels of serum necrosis factor-alpha and interleukin-10 in each group (MP 25, P75 pg/mL)
| External use of mirabilite group (n = 117) | Blank group (n = 117) | P value | ||
| TNF-α | Pre-ERCP 3 h | 1.78 (0.00, 3.39) | 1.30 (0.00, 4.25) | 0.622 |
| Post-ERCP 24 h | 2.42 (1.14, 6.53) | 3.41 (1.63, 8.26) | 0.0321 | |
| P value | 0.0161 | < 0.0011 | ||
| IL-10 | Pre-ERCP 3 h | 3.56 (1.49, 6.01) | 3.49 (1.24, 6.62) | 0.992 |
| Post-ERCP 24 h | 4.60 (2.99, 9.40) | 3.76 (1.74, 7.86) | 0.0111 | |
| P value | < 0.0011 | 0.282 |
- Citation: Zeng JQ, Zhang TA, Yang KH, Wang WY, Zhang JY, Hu YB, Xiao J, Gu ZJ, Gong B, Deng ZH. External use of mirabilite to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in children: A multicenter randomized controlled trial. World J Gastrointest Surg 2023; 15(4): 712-722
- URL: https://www.wjgnet.com/1948-9366/full/v15/i4/712.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i4.712